Close
The development of the proteomics service was funded through core support from the UK National Institute for Health Research Biomedical Research Centre and Unit Funding scheme via the UCLH/University College London Biomedical Research Centre, the UCL Technology Fund and direct funds from NHS England.
The mass spectrometer was funded through generous grants from the Wolfson Foundation and the UCL Amyloidosis Research Fund.
Clinical samples were collected and analysed as part of routine clinical examination. Informed consent was obtained from all patients and clinical care was in accordance with the Declaration of Helsinki.